2020

• Prof Dr José (Joe) Santos
  Innovation: Composing Across Confines
  March 16th 2020 

2019

• Prof Dr Brandon DeKosky
  Large-scale functional analysis of natively paired antibody heavy light chain repertoires
  November 20th 2019
• Prof Dr José Manuel Otero
  Disruptive engineering of viral immunotherapies to create a world free of cancer
  October 23rd 2019
• Prof Dr Renata Stripecke
  Re-Generando: Gene modified dendritic cells and CAR-T cells to rebuild the immune system
  October 8th 2019
• Prof Dr Harald Dinter
  Challenges of the pharmaceutical industry and its implications for collaborators
  May 13th 2019
• Prof Dr Joost Sluijter
  Therapeutics for myocardial repair – moving forward?
  September 14th 2018

2018

• Dr. Jörg Weiske, Head of Protein Technologies 1, Research & Development, Pharmaceuticals at Bayer AG
  Cellular Thermal Shift Assay (CETSA) - Case study @ Protein Technologies (Bayer AG)
  May 17th 2018
• Professor Tom L. Blundell, Cambridge University, UK
  Structure-guided Fragment-based Drug Discovery for Cancer and Tuberculosis: Fighting the Emergence of Resistance
• Prof. Alois Jungbauer, Department of Biotechnology, BOKU, Vienna, Austria
  Separation and Quantification of Virus-like Particles from other extra cellular particles
  March 15th 2018
• David Naveh, Ph.D., MBA, CEO Hemogem, ex- VP and ex-CTO of Bayer Biological Products Worldwide
  Development of Biological Therapeutics for Health and Financial Value Creation - The Pharma Perspective
  March 7th 2018
• Monique M. van Oers, Laboratory of Virology, Wagninngen University, the Netherlands
  Proteins Required for Baculovirus Particle Formation: Relevance for the Development of a Baculovirion-Free Expression System
  March 7th 2018
• Professor Mike Betenbaugh, Johns Hopkins University, USA
  Glycoengineering in CHO cells: Glyco Control-Inside and Out
  February 5th 2018
• Andreas Busch, Head of Drug Discovery - Bayer Pharmaceuticals
  Addressing unmet medical needs: Key drivers for Drug Discovery at Bayer
  January 8th 2018
• Dr. Manel Cascalló, VCN Biosciences SL, Spain
  Oncolytic adenoviruses expressing hyaluronidase: from bench to patients
  January 8th 2018
• Dr. Eda Machado, St. Jude Children's Research Hospital, Memphis, Memphis, Tennessee USA
  Regulated lysosomal exocytosis, an unconventional pathway in cancer progression
  January 8th 2018
• Dr. Andreas Wilmen, Protein Engineering & Assays 2, Bayer AG
  Cardiovascular Research at Bayer
  January 8th 2018
• Dr Hansjörg Hauser, Department of Scientific Strategy, Helmholtz Centre for Infection Research (HZI)
  Viral defence by interferons: A closer look to single cells in populations
  January 8th 2018

2017

• William M. Miller, Chemical and Biological Engineering, Northwestern University Evanston, USA
  A Uniform-Shear-Rate Microfluidic Bioreactor for Real-Time Analysis of Proplatelet Formation and Rapidly-Released Platelets
  June 21st 2017
• Alain Bernard, Biopharma Executive Advisor, Independent advisor to pharma executives · Institut National Agronomique Paris-Grignon
  Knowledge Management
  April 12th 2017
• Felipe Prosper, Director of Hematology and Cell Therapy, Clinica Universidad de Navarra
  Drug and cell delivery systems for cardiac repair
  February 7th 2017
• Simone Kardinahl, Head of Cell & Protein Sciences, Biologics Research, Bayer AG
  DD Biologics – an overview on challenges and opportunities
  January 31st 2017

2016

• Brian Murphy, Celgene Cellular Therapeutics, USA
  Quality by Design and Phase Appropriate Development for Cell Therapies
  November 28th 2016
• Thorsten Lorenz, Novartis Pharma AG, Basel, Switzerland
  Developability Assessment of therapeutic Antibodies - A concept for early Lead Selection
  May 31st 2016
• Katey Owen, Deputy Director for Vaccines Development (CMC), Bill & Melinda Gates Foundation
  Vaccine development and manufacturing for those most in need of vaccines
  April 29th 2016

2015

• Philippe Couttet, Novartis Institutes of Biomedical Research in Basel, Switzerland
  microRNAs as biomarker of drug-induced tissue injury
  December 3rd 2015
• Uwe Marx, CEO, TissUse GmbH
  Humans-on-a-chip” – a paradigm shift in substance testing?!
  November 17th 2015
• Eytan Abraham, Head of Cell Therapy Research & Technology, Lonza, USA
  Stem Cells and Cell Therapy at LONZA
  July 13th 2015
• Hitto Kaufmann, Vice President Technology and Development at Sanofi Biologics, Germany
  Innovation in Biologics Manufacturing
  May 27th 2015
• Thomas Pietzonka, NIBR Biologics Center, Basel
  Changing the Practice of Medicine - Novartis Institutes for Biomedical Research
  May 4th 2015
• Matthias Frech, MERCK KGaA
  Biophysical Methods in Drug Discovery: Combination is Key. The Project Kinetics for Drug Discovery
  February 27th 2015
• Roger-Marc Nicoud, NOVASEP HOLDING S.A.S., FRANCE
  The amazing ability of continuous chromatography to adapt to a moving environment
  February 12th 2015

2014

• Carlos Augusto Pereira, Instituto Butantan, Laboratorio de Imunologia Viral, São Paulo, Brazil
  Vectors carrying heterologous RNA for designing new viral vaccines
  October 23rd 2014
• Christof von Kalle, MD, PhD, National Center for Tumor Diseases (NCT), Heidelberg
  Translational Oncology – the National Center for Tumor Diseases
  October 17th 2014
• Rene Hoet, Heiner Apeler, Lars Linden, Beate Müller-Tiemann, BAYER HEALTHCARE, Global Biologics, Germany
  Protein Biopharmaceuticals @ Bayer: From Discovery to Development
  July 3rd 2014
• Vish Nene, THE INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE (ILRI), NAIROBI - KENYA
  The ILRI Vaccine Biosciences program and improved vaccines for the control of East Coast fever in cattle
  May 16th 2014

2013

• Marc Peschanski, I-STEM (INSERM/UEVE 861, AFM), Evry – France
  Harnessing pluripotent stem cells for pharmacology
  July 18th 2013

2012

• Muntasir Mamun Majumder, FIMM, Institute for Molecular Medicine Finland
  An individualized system medicine platform to guide treatment decisions for therapy-resistant Acute Myeloid Leukemia
  June 21st 2012
• Joachim Klein, Technische Universtat Braunschweig, Germany (jUb.), President, Braunschweig Academy of Sciences, Germany
  Not all chemicals are created equal: The potential of biobased processes and products
  June 1st 2012

2011

• John G. Aunins, Visiting Professor, ITQB, Merck Sharp & Dohme, West Point, New Jersey, USA
  Some Perspectives on Vaccines, Biologicals, and the Pharmaceutical Industry
  November 15th 2011
• Uwe Marx & Mark Rosowski, Technische Universität Berlin, Institute of Biotechnology - Department of Medical Biotechnology
  Vascularized multi-organ systems – the next level of engineering human biology in vitro
  August 4th 2011
• Isabelle Knott, Director, Head of Cell Culture Development, GlaxoSmithKline Biologicals S.A., Rixensart, Belgium
  Cervarix: first human vaccine manufactured with baculovirus expression system
  July 12th 2011
• Héla Kallel, Head, Bioprocess Development Unit, Institut Pasteur de Tunis
  Bioprocess development activities at Institut Pasteur of Tunis
  June 28th 2011
• Regina Grillari, PhD, Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria
  The importance of peeing earnest: urine derived cells as model systems in biology and biomedicine
  June 17th 2011
• Christian Manzke & Etienne Evrard MD, Sartorius Stedim Biotech GmbH – B. Braun AG -Goettingen / Melsungen
  Bioprocess integrated solutions
  Abril 27th 2011
• Brian Lee MD, President, PBS Biotech, Inc, California, EUA
  Mixing methodologies in single use bioreactors - A comparative analysis of consistency across scale
  Abril 4th 2011
• Aleš Štrancar MD PhD, BIA Separations, Ljubljana
  Monolithic chromatography supports – technology platform for the analysis and production of new generation of drug candidates like plasmid DNA and viral vector particles
  March 21st 2011
• Wilfried Bakker MD, Netherlands Vaccine Institute (NVI/RIVM)
  Development and Technology Transfer for Viral Vaccines
  March 15th 2011
• Leo van der Pol MD PhD, Netherlands Vaccine Institute (NVI/RIVM)
  Overview of Vaccine Process Development at RIVM
  March 15th 2011
• Marc Peschanski MD, Scientific Director, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-STEM, INSERM/UEVE) Evry, France
  Pathological modeling, drug discovery and toxicity testing using pluripotent stem cells
  March 2nd 2011
• Leo van der Pol MD
  Overview of Vaccine Process Development at RIVM
  2011

2010

• Nigel Jenkins, National Institute for Cellular Biotechnology, Ireland
  Quality considerations for the production of biopharmaceuticals
  February 2nd 2010
• Hagen von Briesen, Fraunhofer-Institute for Biomedical Engineering
  Global HIV Vaccine Research Cryorepository - GHRC
  January 29th 2010

2009

• Judy Lieberman, Immune Disease Institute and Program in Cellular and Molecular Medicine, Children’s Hospital Boston, Dept of Pediatrics, Harvard Medical School
  Micromanaging cell growth and differentiation
  December 16th, 2009
• Octavio T. Ramírez, Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología Universidad Nacional Autónoma de México
  Bioreactor Scale-Down Studies of Temperature-Inducible Recombinant Protein Production in E. coli
  November 23th, 2009
• Kenneth Lundstrom, PanTherapeutics, Lausanne, Switzerland
  Viral Vectors in Gene Therapy: Special Emphasis on Alphaviruses
  March 11th, 2009
• Kenneth Lundstrom, PanTherapeutics, Lausanne, Switzerland
  Expression of GPCRs in Drug Discovery and Structural Biology
  March 10th, 2009
• Catherine Brenner Jan, DR CNRS, Faculté de Pharmacie, Lausanne, Switzerland
  Signalisation et physiopathologie cardiaque INSERM U769
  February 2009

2008

• Anna Price, In vitro Toxicology Unit,  European Centre for the Validation of Alternative Methods,  Institute of Health and Consumer Protection, European Commission Joint Research Centre, Ispra (VA), Italy
  Re-aggregated brain cell culture as a sensitive in vitro model to evaluate developmental/adult neurotoxicity: application for regulatory requirements
  October 28th, 2008
• Dr. Ing. Reiner Luttmann, Hamburg University of Applied Sciences, Research Center of Bioprocess Engineering and Analytical Techniques
  A comprehensive study in optimal production of Active Pharmaceutical Ingredients with Pichia pastoris
  September 12th, 2008
• Manuel Cánovas, Department of Biochemistry and Molecular Biology B. Faculty of Chemistry. University of Murcia
  Bioprocess Optimization By Using Systems Biology
  September 11th, 2008
• Matthew Croughan, Amgen Bioprocessing Center, Keck Graduate Institute (KGI), Claremont, CA
  The Silver Anniversary of Clinical Protein Production from Recombinant CHO Cell Culture
  June 9th, 2008

Other presentations

• Carlos A. Pereira, Univ. Strasbourg, França and Instituto Butantan, Brasil
  Approaches for preparation of viral antigens from mammalian and insect cells
• John Aunins, MERCK & CO, Philadelphia, EUA and ITQB/UNL, Portugal
  Adenovirus-vectored HIV vaccine development
• Hansjörg Hauser, GBF and Univ. Braunschweig, Germany
  Cancer immune therapy using genetically modified dendritic cells
• Eric J. Kremer, CNRS-UMR, France
• Ursula Sonnewald, Pharmacology & Toxicology Medical School Trondheim, Norway
• Uwe Gottschalk, Sartorius AG, Germany
• Heiko Zimmermann, Fraunhofer IBMT, Germany
• Catherine Brenner, CNRS-UMR, France
• Kenneth Lundstrom, PanTherapeutics, Switzerland
• Brian Kelley, Genentech, USA
• Laura Palomares, México